Extended Data Table 1 Tumor response by BICR

From: Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

  1. Data cutoff: 30 November 2023.
  2. †HR along with 95% CI was estimated using a stratified Cox proportional hazards model. The P value was calculated using the Cochran–Mantel–Haenszel method stratified by lines of prior therapy (2 or 3 versus >3) and presence of liver metastases (yes versus no). The exact one-sided P value was 2.2 × 10−9.
Back to article page